ASCO 2024 | CheckMate 67T: subcutaneous versus intravenous nivolumab in ccRCC
Maria Bourlon, MD, MS, El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, discusses findings from Phase III CheckMate 67T trial (NCT04810078), which compared subcutaneous versus intravenous administration of nivolumab in patients with pre-treated advanced or metastatic clear cell renal cell carcinoma (ccRCC). Route of administration did not affect outcomes, nor did the weight of the patient. Reported side effects were additionally similar, where patients receiving subcutaneous nivolumab produced more antibodies. In terms of patient related outcomes (PROs), patients were more satisfied with subcutaneous nivolumab in the long term. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Leadership – BMS
Honoraria – BMS; Tecnofarma; Tecnofarma
Consulting or Advisory Role – Asofarma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Gilead Sciences; Janssen Oncology; Merck; MSD; MSD Oncology; Novartis; Novartis; Pfizer
Speakers’ Bureau – Asofarma; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Ipsen; Janssen Oncology; Medicamenta; Merck; MSD Oncology; Pfizer; Tecnofarma
Research Funding – Janssen Oncology (Inst); Pfizer
Expert Testimony – Asofarma
Travel, Accommodations, Expenses – Asofarma; Bristol-Myers Squibb (Mexico); Janssen-Cilag; MSD Oncology; Pfizer
Other Relationship – Sanofi
